ATE339201T1 - Lasofoxifen enthaltende zusammensetzungen - Google Patents

Lasofoxifen enthaltende zusammensetzungen

Info

Publication number: ATE339201T1
Authority: AT; Austria
Prior art keywords: lasofoxifen; compositions containing; lasofoxifene; effect; compositions
Prior art date: 1999-09-29

Application number

AT00308152T

Other languages

English (en)

Inventor

David Duane Thompson

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-29

Filing date

2000-09-19

Publication date

2006-10-15

2000-09-19 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2006-10-15 Application granted granted Critical

2006-10-15 Publication of ATE339201T1 publication Critical patent/ATE339201T1/de

Links

239000000203 mixture Substances 0.000 title abstract 2
GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 abstract 2
229960002367 lasofoxifene Drugs 0.000 abstract 2
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Reproductive Health (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Indole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyrrole Compounds (AREA)

AT00308152T 1999-09-29 2000-09-19 Lasofoxifen enthaltende zusammensetzungen ATE339201T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US15665299P	1999-09-29	1999-09-29

Publications (1)

Publication Number	Publication Date
ATE339201T1 true ATE339201T1 (de)	2006-10-15

Family

ID=22560457

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00308152T ATE339201T1 (de)	1999-09-29	2000-09-19	Lasofoxifen enthaltende zusammensetzungen

Country Status (20)

Country	Link
US (1)	US6436977B1 (de)
EP (1)	EP1092431B1 (de)
JP (1)	JP2001097862A (de)
KR (1)	KR100468246B1 (de)
AT (1)	ATE339201T1 (de)
AU (1)	AU781828B2 (de)
CA (1)	CA2321369C (de)
CO (1)	CO5200833A1 (de)
CY (1)	CY1105235T1 (de)
DE (1)	DE60030654T2 (de)
DK (1)	DK1092431T3 (de)
ES (1)	ES2269071T3 (de)
HU (1)	HUP0003836A3 (de)
IL (1)	IL138634A (de)
MY (1)	MY121519A (de)
NZ (2)	NZ507200A (de)
PE (1)	PE20010680A1 (de)
PT (1)	PT1092431E (de)
TW (1)	TWI224001B (de)
ZA (1)	ZA200005141B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5968547A (en)	1997-02-24	1999-10-19	Euro-Celtique, S.A.	Method of providing sustained analgesia with buprenorphine
AU2756602A (en) *	2001-04-25	2002-10-31	Pfizer Products Inc.	Methods and kits for treating depression or preventing deterioration of cognitive function
EP1404333A1 (de)	2001-07-06	2004-04-07	Endo Pharmaceuticals Inc.	Kontrolliert freisetzende formulierungen von oxymorphon
PA8576201A1 (es) *	2002-07-10	2004-05-26	Pfizer Prod Inc	Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
WO2008058287A1 (en) *	2006-11-10	2008-05-15	Syndax Pharmaceuticals, Inc.	COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
US20100298270A1 (en) *	2007-07-23	2010-11-25	Syndax Pharmaceuticals, Inc.	Novel Compounds and Methods of Using Them
US20100267779A1 (en) *	2007-07-23	2010-10-21	Syndax Pharmaceuticals, Inc.	Novel Compounds and Methods of Using Them
US20090149511A1 (en) *	2007-10-30	2009-06-11	Syndax Pharmaceuticals, Inc.	Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009067453A1 (en) *	2007-11-19	2009-05-28	Syndax Pharmaceuticals, Inc.	Combinations of hdac inhibitors and proteasome inhibitors
CA2725390C (en) *	2008-04-08	2014-09-23	Syndax Pharmaceuticals, Inc.	Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
PL3525774T3 (pl)	2016-10-11	2022-04-25	Duke University	Leczenie lazofoksyfenem raka piersi er+
WO2019199891A1 (en)	2018-04-10	2019-10-17	Duke University	Lasofoxifene treatment of breast cancer
GB202116903D0 (en)	2021-11-18	2022-01-05	Sermonix Pharmaceuticals Inc	Lasofoxifene treatment of aromatase-resistant er+ cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5296486A (en)	1991-09-24	1994-03-22	Boehringer Ingelheim Pharmaceuticals, Inc.	Leukotriene biosynthesis inhibitors
US5366965A (en) *	1993-01-29	1994-11-22	Boehringer Mannheim Gmbh	Regimen for treatment or prophylaxis of osteoporosis
US5552412A (en) *	1995-01-09	1996-09-03	Pfizer Inc	5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL120266A (en)	1996-02-28	2005-05-17	Pfizer	Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
GB2324726A (en) *	1997-05-01	1998-11-04	Merck & Co Inc	Combination Therapy for the Treatment of Osteoporosis
EP1004306A3 (de)	1998-08-06	2000-06-07	Pfizer Products Inc.	Estrogen Agonisten/Antagonisten
EP1086692A3 (de)	1999-07-28	2003-07-09	Pfizer Products Inc.	Oestrogen Agonisten und Antagonisten für mehrere Indikationen

2000
- 2000-09-06 US US09/656,273 patent/US6436977B1/en not_active Expired - Lifetime
- 2000-09-11 AU AU56618/00A patent/AU781828B2/en not_active Ceased
- 2000-09-19 DK DK00308152T patent/DK1092431T3/da active
- 2000-09-19 DE DE60030654T patent/DE60030654T2/de not_active Expired - Lifetime
- 2000-09-19 ES ES00308152T patent/ES2269071T3/es not_active Expired - Lifetime
- 2000-09-19 AT AT00308152T patent/ATE339201T1/de not_active IP Right Cessation
- 2000-09-19 PT PT00308152T patent/PT1092431E/pt unknown
- 2000-09-19 EP EP00308152A patent/EP1092431B1/de not_active Expired - Lifetime
- 2000-09-21 IL IL138634A patent/IL138634A/en not_active IP Right Cessation
- 2000-09-25 TW TW089119761A patent/TWI224001B/zh not_active IP Right Cessation
- 2000-09-26 PE PE2000001009A patent/PE20010680A1/es not_active Application Discontinuation
- 2000-09-26 ZA ZA200005141A patent/ZA200005141B/xx unknown
- 2000-09-26 KR KR10-2000-0056344A patent/KR100468246B1/ko not_active Expired - Fee Related
- 2000-09-26 MY MYPI20004477A patent/MY121519A/en unknown
- 2000-09-27 CA CA002321369A patent/CA2321369C/en not_active Expired - Fee Related
- 2000-09-28 NZ NZ50720000A patent/NZ507200A/xx unknown
- 2000-09-28 HU HU0003836A patent/HUP0003836A3/hu unknown
- 2000-09-28 NZ NZ51641300A patent/NZ516413A/xx unknown
- 2000-09-29 JP JP2000297908A patent/JP2001097862A/ja active Pending
- 2000-09-29 CO CO00074167A patent/CO5200833A1/es not_active Application Discontinuation
2006
- 2006-09-20 CY CY20061101350T patent/CY1105235T1/el unknown

Also Published As

Publication number	Publication date
EP1092431A2 (de)	2001-04-18
HU0003836D0 (en)	2000-12-28
ES2269071T3 (es)	2007-04-01
CO5200833A1 (es)	2002-09-27
DE60030654T2 (de)	2007-04-05
IL138634A (en)	2006-08-01
PT1092431E (pt)	2006-12-29
IL138634A0 (en)	2001-10-31
HUP0003836A3 (en)	2002-09-30
TWI224001B (en)	2004-11-21
DK1092431T3 (da)	2006-12-18
CA2321369A1 (en)	2001-03-29
ZA200005141B (en)	2002-03-26
KR20010061927A (ko)	2001-07-07
PE20010680A1 (es)	2001-06-29
DE60030654D1 (de)	2006-10-26
NZ516413A (en)	2004-12-24
US6436977B1 (en)	2002-08-20
EP1092431B1 (de)	2006-09-13
HUP0003836A2 (hu)	2001-10-28
JP2001097862A (ja)	2001-04-10
MY121519A (en)	2006-01-28
AU781828B2 (en)	2005-06-16
KR100468246B1 (ko)	2005-01-27
NZ507200A (en)	2004-12-24
AU5661800A (en)	2001-04-05
CA2321369C (en)	2007-07-17
EP1092431A3 (de)	2002-02-13
CY1105235T1 (el)	2010-03-03

Legal Events

Date

Code

Title

Description

2007-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1092431

Country of ref document: EP

2010-06-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE312843T1 (de)	2005-12-15	Neues cyclosporin mit verbesserter wirkung
DK1157037T3 (da)	2003-11-24	GCSF-konjugater
DE69909768D1 (de)	2003-08-28	Xanthangummi enthaltende gelbildende ophthalmische zusammensetzungen
ATE198143T1 (de)	2001-01-15	Zahnpasten
EE200100594A (et)	2003-02-17	Uudsed ravimikompositsioonid, mis põhinevad antikolinergiliselt toimivatel ühenditel ja ß-mimeetikumidel
DE69611165D1 (de)	2001-01-11	Zahnplegemitteln
DE69519580D1 (de)	2001-01-11	Zahnpflegemitteln
DE69931925D1 (de)	2006-07-27	2-chinolonen enthaltende arzneimittel
IL128425A0 (en)	2000-01-31	Taxane derivatives their preparation and pharmaceutical compositions containing them
IL144026A0 (en)	2002-04-21	Phenylphenanthridine derivatives and pharmaceutical compostions containing the same
TR200003787A3 (tr)	2001-07-23	Kararli yavas salimli oral dozaj bilesimi.
FI972168L (fi)	1997-05-21	Oraaliset koostumukset, jotka sisältävät ondansetronia
SE9802729D0 (sv)	1998-08-13	Novel Compounds
HUP0202489A3 (en)	2006-06-28	Compositions containing solubilized, acid-enhanced antiperspirant active
ATE339201T1 (de)	2006-10-15	Lasofoxifen enthaltende zusammensetzungen
MXPA03003687A (es)	2003-08-07	Composiciones para cuidado dental.
HUP0102671A3 (en)	2002-04-29	Immunosupressive pharmaceutical compositions containing 2',2'-difluoro-nucleoside analogues
ATE236657T1 (de)	2003-04-15	Konjugat, umfassend einen folsäureantagonisten und einen träger
TWI347948B (en)	2011-09-01	Novel 2',5'-oligoadenylic acid compositions
MXPA04005226A (es)	2004-10-11	1,3-diarilprop-2-en-1-onas, composiciones que las contienen y su utilizacion.
NO20021429D0 (no)	2002-03-21	1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
ITMI20030827A1 (it)	2004-10-19	Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
IL162880A0 (en)	2005-11-20	Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyk) dodecanoic acid
HUP0204144A3 (en)	2003-07-28	N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses
IT1282755B1 (it)	1998-03-31	Composizioni farmaceutiche orali contenenti chetotifene fumarato ad azione ritardo.